CS-002 Allergan Botox Origin Patent 'Does Not Exist' — Alan B. Scott's 1973 IOVS Paper (Pharmacologic weakening of extraocular muscles) Was Public Disclosure That Voided Patentability, and Scott's Lawyers Decided Against Filing — A 'Patent Absence' Excavation, the Second Installment of Treating 'Patent Absence' as a Primary Source (Day 10 ep42 Köhler-Milstein Monoclonal Antibody Was the First). DB Number US4932936 Is University of Minnesota's Spastic Urethral Sphincter Treatment Device, Completely Unrelated.

About This Excavation Memo

This is the excavation candidate where the absence of the primary source itself is the discovery. The Allergan Botox (onabotulinumtoxinA) origin patent does not exist. Scott's 1973 IOVS paper voided patentability via prior public disclosure, and his lawyers decided against filing. This memo records the second installment of AI Archaeology's 'treat patent absence as a primary source' approach, structurally identical to Day 10 ep42 PH-004 Köhler-Milstein monoclonal antibody. We also confirmed that DB number US4932936 is a complete mix-up (University of Minnesota's spastic urethral sphincter treatment device).

Why Excavate This?

We executed Day 22 hand-off recommendation #1: 'final resolution of the unverified 3 entries = retrieve CS-002 Botox US4932936 Claim 1 verbatim.' Pulling US4932936 from Google Patents, the title is 'Method and device for pharmacological control of spasticity', the Original Assignee is University of Minnesota System (not Allergan), the inventors are Dennis D. Dykstra / Abraham A. Sidi co-invention (not Alan Scott), Priority 1988-01-29, Filing 1988-01-29, Grant 1990-06-12, currently Expired - Fee Related (lapsed for non-payment of maintenance fees). Claim 1 verbatim describes a device that inserts an electrode-needle / catheter via a cystoscope working channel and injects botulinum toxin A into the spastic urethral sphincter for denervation and relaxation — a spastic urethral sphincter treatment device, unrelated to Allergan Botox, Oculinum, strabismus, blepharospasm, or aesthetic indication. Alan Scott / Oculinum is mentioned only in the background art section as prior art; the inventors and assignee fields do not list them.

We then searched for the correct origin patent number for Allergan Botox (onabotulinumtoxinA). The origin patent itself does not exist — confirmed across Wikipedia Alan B. Scott + Medicine 2023 paper + ScienceDirect obituary 'Professor Alan B. Scott 1932-2021: The inventor of Botox' + 5 industry articles.

Scott's lab had a patent policy under which they declared items or processes of possible patentability, but the lawyers found that their 1973 paper had published the concepts of how the toxin worked, so they never applied for a patent. Without a patent, no pharma company would take over manufacturing. As a result, Scott took out a loan on his home and developed a corporation, Oculinum Inc., to handle this project.

— Early development history of Botox (onabotulinumtoxinA). Medicine. 2023; 102(28).

That is, Scott's lawyers determined that the 1973 paper Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol Vis Sci 12: 924-927, 1973 had publicly disclosed the invention's core — botulinum toxin A injection into extraocular muscles for strabismus correction — voiding patentability. Scott went without a patent and instead took a home-equity loan to found Oculinum Inc. ('Oculinum' = 'eye aligner'), handled manufacturing and clinical trials in-house, obtained FDA approval on 1989-12-29 (strabismus and blepharospasm in patients aged 12 and over), and sold to Allergan in 1991 (rebranded as Botox).

This is structurally identical to Day 10 ep42 PH-004 Köhler-Milstein monoclonal antibody. The 1975 Nature 256:495-497 paper publicly disclosed the invention's core, and MRC LMB Cambridge wrote 'it is not immediately obvious what patentable features are at present disclosed in the Nature paper,' declining to file. Three years later, Wistar Institute (Koprowski/Croce) obtained the derivative US4172124A 'Method of producing tumor antibodies' (peripheral, limited scope). In Botox's case, the origin 'medical use of botulinum toxin A' itself was unpatented; what Allergan acquired in 1991 from Oculinum was not patent rights but manufacturing know-how, FDA approval rights, the Oculinum brand, and inventory.

Patent Basic Info

DB Number US4932936 (mix-up confirmed)

Item	Content
Number	US4932936 (real, but not Allergan Botox)
Title	Method and device for pharmacological control of spasticity
Original Assignee	University of Minnesota System
Current Assignee	University of Minnesota Twin Cities / University of Minnesota System
Inventors	Dennis D. Dykstra / Abraham A. Sidi (two co-inventors)
Priority	1988-01-29
Filing	1988-01-29
Grant	1990-06-12
Legal status	Expired - Fee Related (lapsed for non-payment of maintenance fees)
Use	Spastic urethral sphincter treatment (electrode-needle + botulinum toxin A injection via cystoscope working channel)
Relation to Allergan / Scott	None. Scott is mentioned in this patent's background art section as prior art only; not an inventor or assignee

Anchor Document Replacing the 'Non-existent' Origin Patent

Since the Allergan Botox origin patent does not exist, the primary source this memo anchors to is Scott's 1973 paper:

Item	Content
Document	Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol Vis Sci 12: 924-927, 1973
Authors	Alan B. Scott / Arthur Rosenbaum / Carter C. Collins (three co-authors)
Journal	Investigative Ophthalmology & Visual Science (IOVS), ARVO journal
Content	Reports botulinum toxin A injection into extraocular muscles in 8 monkeys and 42 adult human strabismus patients; first clinical-utility report
Role	The 'public disclosure' that voided later patentability

Subsequent Scott chronology:

1977: First strabismus patient injection; Smith-Kettlewell Eye Research Institute (San Francisco), continued clinical work
1980-1981: Reports clinical series of 8 monkeys + 42 adult human patients in Ophthalmology
1980s: Scott himself founded Oculinum Inc., funded manufacturing and trials via home-equity loan (pharma companies declined due to patent absence)
1989-12-29: FDA approves Oculinum for strabismus and blepharospasm (12+ years old, with dystonia) (U.S. License)
1991: Scott sells Oculinum Inc. rights to Allergan; Allergan rebrands as Botox
1992: Carruthers couple (J. Carruthers / D. Carruthers, Canada) reports off-label cosmetic effects on glabellar lines
2002-04-15: FDA approves Botox Cosmetic for glabellar lines, the trigger for onabotulinumtoxinA's cosmetic-blockbuster status
2021: Alan B. Scott passes away (age 89), eulogized as 'The inventor of Botox'

Claim 1 (Cannot Retrieve / Absent)

The Allergan Botox origin patent does not exist, so there is no Claim 1 verbatim. The anchor this memo places instead is Scott's 1973 paper title and abstract:

Pharmacologic weakening of extraocular muscles — Scott AB, Rosenbaum A, Collins CC. Invest Ophthalmol Vis Sci 12: 924-927, 1973.

This title and abstract publicly disclosed the invention's core — 'botulinum toxin A injection into extraocular muscles for strabismus correction' — voiding later patentability. Structurally identical to Day 10 ep42 PH-004 Köhler-Milstein (Nature 1975 256:495-497).

The Claim 1 verbatim of University of Minnesota US4932936 (the mix-up number) describes a spastic urethral sphincter treatment device — different from Allergan Botox. It is irrelevant to this memo's storyline, so we omit the verbatim quote.

Modern-Day Connection

Four impacts of 'patent absence' on the modern cosmetic / medical aesthetic industry:

Allergan's market position is not patent-derived: After the 1991 Oculinum acquisition, Allergan's market dominance is not from origin-patent protection (typically 20-year term). It is built on (a) Botox brand inheritance from Oculinum, (b) FDA approval-rights monopoly, (c) botulinum toxin A purification / manufacturing know-how (trade secret), and (d) a portfolio of follow-on indication patents (glabellar lines, axillary hyperhidrosis, migraine, overactive bladder)
Late-comer biosimilar entry was early because of patent absence: abobotulinumtoxinA (Dysport, Ipsen, UK Speywood origin), incobotulinumtoxinA (Xeomin, Merz, Germany), prabotulinumtoxinA (Jeuveau, US), daxibotulinumtoxinA (Daxxify, Revance), etc. — entry of biosimilars / heterologous botulinum toxin A formulations was relatively early because of the absence of a Scott-origin patent
Botox Cosmetic 2002 FDA approval is a separate axis: The glabellar-lines aesthetic approval is supported by Allergan's follow-on indication / composition patent portfolio, independent of the Oculinum origin. These follow-on patents are expiring, and the 2020s have seen accelerated entry of further competitors like Daxxify and Letybo (letibotulinumtoxinA, Hugel)
Economic scale of 'patent absence': Botox alone now grosses over $3B/year (post-Allergan, AbbVie). Had Scott obtained an origin patent, he could have captured all of it; instead, due to patent absence, he is reported to have received around $9M from the Oculinum sale. The most successful biopharmaceutical in history paid its inventor relatively little — a historical irony

Unverified

Body of Scott's 1973 paper (IOVS is an ARVO journal; requires PubMed / library access; this memo only references abstract / citation info)
Scott's lab patent policy formal document (internal materials including the lawyers' opinion are not public)
Specific amount Allergan paid for the 1991 Oculinum acquisition (industry estimates around $9M, but the precise payment to Scott is not public)
Exhaustive list of onabotulinumtoxinA-related indication / composition patents Allergan obtained 1991-2002
Primary source of Allergan's patent portfolio at the time of the 2002 FDA cosmetic approval
Body of the Carruthers couple's 1992 paper (off-label glabellar-lines report)

Next Actions

Retrieve Scott 1973 paper body: PubMed / academic library access. Establish the AI Archaeology method 'use a paper as primary source to anchor patent absence'
Catalog Allergan follow-on indication patents: Exhaustive Google Patents assignee search for onabotulinumtoxinA-related Allergan patents 1991-2010. Identify the patent group supporting the 2002 Botox Cosmetic FDA approval
Establish 'Patent Absence' series with Day 10 ep42 PH-004: Systematize the cases where the core invention falls into the public domain through paper-precedence in pharma / cosmetic subseries. Genomic Archaeology (David Reich ancient DNA research) may have similar structure
Position of this memo: First installment of the fourth form (absence) of cosmetic-subseries DB reliability problems — alongside Day 22 ep79 (misreading) and ep80 (information wall). Day 22 completes the four-form set: mix-up / misreading / information wall / absence